Navigation Links
Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year
Date:9/7/2007

LONDON, Sept. 7 /PRNewswire/ -- Chiltern, a leading global research organization, is pleased to announce that last night Richard Schulz, Chiltern's Country Manager for the Czech Republic, received GCPj's "Best Clinical Researcher" of the year award. The award ceremony was held in London's historic Gibson Hall.

Richard was selected from amongst his peers by a panel of judges who reviewed his achievements in the implementation and successful conclusion of clinical trials. The judging panel was composed of a group of senior industry experts. "I am delighted to receive this award," said Richard,

"it is a great honor for me, my team and Chiltern. It is always gratifying to see ones efforts and dedication rewarded at such a high profile and well recognized industry event."

"Chiltern is delighted for Richard who has performed a tremendous job in rapidly growing our operations in the Czech Republic, Slovakia, Hungary and Romania," commented Lewis Cameron, Executive Vice President Europe. He added, "Richard has implemented processes that have increased efficiency and communications to the benefit of our sponsors in Central and Eastern Europe and he exemplifies the talent and high quality clinical research personnel Chiltern employs worldwide."

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience of running and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs more than 1000 people with 18 offices across the United States, Europe and in India. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.

For More Information Contact:

Catherine Lemercier

Chiltern International, Inc.

2111 Palomar Airport Road

Suite 200

Carlsbad

CA 92011

USA
'/>"/>

SOURCE Chiltern International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Richard Thiemes latest Islands in the Clickstream
2. Medical College receives $377K to study brain disease
3. Lucigen receives $750K grant to boost biofuel yields
4. Medical College receives $1.4M cancer grant
5. Wisconsin biotech firm receives $107K NIH grant
6. InvivoSciences receives NIH grant for heart technology
7. Medical College receives $11 million grant to study high blood pressure
8. Madison business receives $115,000 of new state biofuels funding
9. Superior receives funds for technical training
10. UWM receives state funding for plastics research
11. GEs Centricity EHR receives federal certification

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...eMarbleEnergyCorp.announcedtodaythatthecompanyandt...lyawarded$2millionbyWashingtonState,sCommunityEcon...nershiptoconstructthestate,sfirstspecialtybiochemi...tmentwillsignificantlyspeedthedevelopmentofourbior...dBlueMarbleEnergyCEOKellyOgilvie."Wearegratefultot...
(Date:11/24/2009)...etforpatientswithadvanced-stage,orrecurrentendomet...rstCall/-AEternaZentarisInc.(NASDAQ: AEZS ;TSX:AEZ...usedonendocrinetherapyandoncology,todayannouncedpo...ytotoxicpeptideconjugate,AEZS-108(formerlyAN-152),....Inapersonalizedhealthcareapproach,thestudyselecte...
(Date:11/24/2009)...rstCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),theglo...edthatithassubmittedaMAAtotheEuropeanMedicinesAgen...enttherapyindevelopment,forthetreatmentofType1Gauc...elaglucerasealfathathasbeensubmitted,withprevious,...donaglobalsupplyshortageofthecurrentlyapprovedandm...
(Date:11/24/2009)...swire-FirstCall/--GenomicHealth,Inc.(Nasdaq: GHDX ...tiveChairman,willpresentatthe21stAnnualPiperJaffra...er1,2009at10:00a.m.ET. ,, Toaccesstheliveandsub...InvestorRelationssectionofGenomicHealth,swebsiteat...othewebsiteatleast15minutespriortothebeginningofth...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Genomic Health to Present at Piper Jaffray Health Care Conference 2
...: SHP,NASDAQ: SHPGY ), the global specialty biop...ion agreement with GlaxoSmithKline plc (NYSE: GS...apsules CII with the aim of,improving recognition ...greement covers the United States and will more th...ales effort for VYVANSE by adding over 600 sales,r...
...eted product, a new vaccine against Japanese Encep... - Commercial product launch in the U.S. planned f...E: ICLL) today announced that the U.S. Food and Dr...vaccine for the prevention of Japanese Encephaliti...vaccine - the only such product currently manufact...
...nsulting US, a division of London-based Double Hel...ent of Ann Stuchiner to the position of Vice Presi... highly experienced strategic pricing, reimburseme...perience across the healthcare industry, which pro...n the pharmaceutical, biotechnology and medical de...
Other Biology Technology:Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 2Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 3Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 4Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 5Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 6Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 2Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 3Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 4Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division 2
(Date:11/24/2009)... NEW YORK (November 24, 2009) -- The Wildlife Con...evealing that the last remaining population of Sib... to the rising tide of poaching and habitat loss. ...rm Russian officials of what needs to be done to p...t cat. , The report was released by...
(Date:11/24/2009)... (November 24, 2009) New research on bacterial co...tems reveals predictable temporal patterns, sugges...s markers for monitoring climate change in the pol... Proceedings of the National Academy of Sciences ... the six rivers shifted synchronously over time, c...
(Date:11/23/2009)...C. The community-associated strain of the deadly ...nt to most common antibioticsposes a far greater h...ts way into hospitals, according to a study in the... , The new threat is easily picked up in fitnes...s increased the overall burden of MRSA within hosp...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2New study finds MRSA on the rise in hospital outpatients 2Nurses AFL CIO Unions to Host Michael Moore and Special Screening of New Film at AFL CIO Convention 56663 1Nurses AFL CIO Unions to Host Michael Moore and Special Screening of New Film at AFL CIO Convention 56663 2GENova appoints Director of Asian business development 56661 1GENova appoints Director of Asian business development 56661 2Vita Tech International Inc Donates One Ton of Vitamins To Polio Treatment Centers in Guinea West Africa 13950 1
...ns School of Medicine and their colleagues have fo...ptor in addition to their own can acquire new colo... rapidly to new sensory information than anticipat...lso suggests that when the first ancestral primate...0 million years ago, it probably experienced immed...
...School of Medicine & Dentistry at The Universi...Edinburgh, have discovered a way to kill the cysti...se investigators, under the leadership of Dr. Migu...ogy, have had their research published in the May ...ted in Nature Reviews/Microbiology. , B. cenocepa...
...pment of new neurons in specific brain regions aff...n, new research shows. How these new neurons stor...how they can affect learning and memory in adults...., of the Salk Institute, found that experience enh...called the dentate gyrus, and that more of these n...
Other Biology News:Making mice with enhanced color vision 2Making mice with enhanced color vision 3Key found to kill cystic fibrosis superbug 2Experience affects new neuron survival in adult brain; study sheds light on learning, memory 2
RNA 6000 Nano Chip Kit from Agilent Technologies
Mouse Anti-Human ALPK3 Monoclonal Antibody, Unconjugated, Clone 4G4 from Abnova Corporation
...Lines ,High Quality, Functionally-Validated, Ion C...or having a critical role in nerve and muscle func... CNS and the heart. Drugs that modulate ion channe...ch as neuropathic pain, cardiac arrhythmia, hypert...
Mouse Anti-Human CD320 Polyclonal Antibody, Unconjugated from Abnova Corporation
Biology Products: